Summary
0Q1N Chart
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare
Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples, making it attractive for income-focused investors despite recent underperformance. The company faces significant patent cliffs, risking about $20 billion in annual revenue, and is unlikely to avoid revenue declines in the next few years. Management is responding with cost cuts, acquisitions, and licensing deals, but growth prospects remain limited and stability is a key concern.
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Pfizer Inc. (NYSE:PFE ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider Great. Good morning, everyone, and welcome to our 46th Annual Global Healthcare Conference.
Pfizer Inc. Dividends
 0Q1N 1 month ago | Other | $0.43 Per Share |
| 0Q1N 4 months ago | Other | $0.43 Per Share |
| 0Q1N 7 months ago | Other | $0.42 Per Share |
| 0Q1N 10 months ago | Other | $0.42 Per Share |
| 0Q1N 9 May 2024 | Other | $0.42 Per Share |
Pfizer Inc. Earnings
| 28 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 28 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | 0.07 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | 0.78 EPS |
| 0Q1N 1 month ago | Other | $0.43 Per Share |
| 0Q1N 4 months ago | Other | $0.43 Per Share |
| 0Q1N 7 months ago | Other | $0.42 Per Share |
| 0Q1N 10 months ago | Other | $0.42 Per Share |
| 0Q1N 9 May 2024 | Other | $0.42 Per Share |
| 28 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 28 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | 0.07 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | 0.78 EPS |
Pfizer Inc. (0Q1N) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Pfizer Inc. ever had a stock split?
Pfizer Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Dr. Albert Bourla D.V.M., Ph.D. CEO | LSE Exchange | US7170811035 ISIN |
| US Country | 81,000 Employees | 24 Jan 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Overview
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.
Products and Services
- Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
- Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
- Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
- Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
- Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
- Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
- Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
- Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.
Contact Information
